How to choose menopause symptom treatment, and why diabetes risk may rise during the transition
Latest news on WhatsApp أجدد الأخبار على واتسابMenopause and the years leading up to it can bring a wide range of symptoms, from hot flashes and night sweats to sleep disruption, mood changes, and genitourinary symptoms such as vaginal dryness and painful sex. Medical groups emphasize that there is no single “best” therapy for everyone, and that treatment choices should be individualized based on symptom severity, medical history, and a patient’s cardiovascular, cancer, and clotting risk profile, with periodic reassessment over time.
Canadian guidance from the Canadian Menopause Society and Society of Obstetricians and Gynaecologists of Canada states that menopausal hormone therapy is the most effective option for vasomotor symptoms, and can generally be initiated safely in people who are under age 60 or within 10 years of menopause onset, provided there are no contraindications and the regimen is tailored to the individual.
The guidance also notes that people with a uterus typically require progestogen alongside estrogen to protect the endometrium, while estrogen alone may be used after hysterectomy. For primarily local genitourinary symptoms, low-dose vaginal estrogen is often used because it largely acts locally rather than systemically.
For those who cannot, or prefer not to, use hormone therapy, Canadian sources list non-hormonal prescription options that may reduce hot flashes, including certain SSRI/SNRI medications, gabapentin, oxybutynin, and clonidine. Newer non-hormonal therapies have also emerged, including the NK3 receptor antagonist fezolinetant, which has been authorized in Canada for vasomotor symptoms associated with menopause.
Researchers say the menopause transition can also coincide with metabolic changes, including shifts toward central adiposity and higher insulin resistance, which may contribute to higher odds of impaired glucose regulation in some women, especially when combined with aging, weight gain, physical inactivity, and poor sleep. Recent cohort research has reported an association between frequent vasomotor symptoms and a higher risk of developing type 2 diabetes, suggesting that bothersome symptoms may warrant broader cardiometabolic risk assessment.
At the same time, other research indicates that the timing or type of menopause may not be an independent driver of diabetes risk once other factors are accounted for, reinforcing that prevention and screening efforts should focus on modifiable risks and overall health profile rather than a single variable
